Show detailed solution

1. In 2009, the RV144 randomized, doubleblinded, efficacy trial in Thailand reported that a primeboost human immunodeciency virus (HIV) vaccine regimen conferred about 30% protection against HIV acquisition, but different analyses seemed to give conflicting results. Here, focus is on individuals in the general population in Thailand, mostly at heterosexual risk, 61% of which were men, randomized in the intention to treat population, excluding subjects found to be HIV positive at the time of randomization. The press release reported r1 = 51 infected among n; = 8197 who have taken the vaccine, to be compared with r; = 74 infected among a; = 8198 who have taken a placebo. at. Assume that no prior information is available on the probability of success :9. Determine the posterior distribution of the vaccine and placebo group? b. Assume that in the previous trial in 2009 was based on 500 patients in both the treated and control group, and reSUIted in 3 infected individual in the vaccine group and 5 in the control group. Determine the posterior distribution of the vaccine and placebo group